TY - JOUR
T1 - Disease- and Therapy-Specific impact on Humoral immune Responses to cOViD-19 Vaccination in Hematologic Malignancies
AU - Chung, David J.
AU - Shah, Gunjan L.
AU - Devlin, Sean M.
AU - Ramanathan, Lakshmi V.
AU - Doddi, Sital
AU - Pessin, Melissa S.
AU - Hoover, Elizabeth
AU - Marcello, Lee Ann T.
AU - Young, Jennifer C.
AU - Boutemine, Sawsan R.
AU - Serrano, Edith
AU - Sharan, Saumya
AU - Momotaj, Saddia
AU - Margetich, Lauren
AU - Bravo, Christina D.
AU - Papanicolaou, Genovefa A.
AU - Kamboj, Mini
AU - Mato, Anthony R.
AU - Roeker, Lindsey E.
AU - Hultcrantz, Malin
AU - Mailankody, Sham
AU - Lesokhin, Alexander M.
AU - Vardhana, Santosha A.
AU - Knorr, David A.
N1 - Funding Information:
The authors thank the patients and healthy volunteers for participating in the trial. They also thank the nurses, advanced practice providers, research staff, and physicians of the Laboratory Medicine, Leukemia, Lymphoma, and Multiple Myeloma Services. Supplementary Figure S1 was created with BioRender.com. This study was supported by The Society of Memorial Sloan Kettering (D.J. Chung), NIH/NCI 5K08CA248966–02 (D.A. Knorr), Leukemia & Lymphoma Society (S.A. Vardhana), Pershing Square Sohn Cancer Research Alliance (S.A. Vardhana), and Conrad Hilton Foundation (S.A. Vardhana). This study was also funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748 and NIH P01 CA23766.
Publisher Copyright:
©2021 American Association for Cancer Research.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Coronavirus disease-19 (COVID-19) vaccine response data for patients with hematologic malignancy, who carry high risk for severe COVID-19 illness, are incomplete. In a study of 551 hematologic malignancy patients with leukemia, lymphoma, and multiple myeloma, anti–SARS-CoV-2 spike IgG titers and neutralizing activity were measured at 1 and 3 months from initial vaccination. Compared with healthy controls, patients with hematologic malignancy had attenuated antibody titers at 1 and 3 months. Furthermore, patients with hematologic malignancy had markedly diminished neutralizing capacity of 26.3% at 1 month and 43.6% at 3 months, despite positive seroconversion rates of 51.5% and 68.9% at the respective time points. Healthy controls had 93.2% and 100% neutralizing capacity at 1 and 3 months, respectively. Patients with leukemia, lymphoma, and multiple myeloma on observation had uniformly blunted responses. Treatment with Bruton tyrosine kinase inhibitors, venetoclax, phosphoinositide 3-kinase inhibitors, anti-CD19/CD20–directed therapies, and anti-CD38/B-cell maturation antigen–directed therapies substantially hindered responses, but single-agent immunomodulatory agents did not.
AB - Coronavirus disease-19 (COVID-19) vaccine response data for patients with hematologic malignancy, who carry high risk for severe COVID-19 illness, are incomplete. In a study of 551 hematologic malignancy patients with leukemia, lymphoma, and multiple myeloma, anti–SARS-CoV-2 spike IgG titers and neutralizing activity were measured at 1 and 3 months from initial vaccination. Compared with healthy controls, patients with hematologic malignancy had attenuated antibody titers at 1 and 3 months. Furthermore, patients with hematologic malignancy had markedly diminished neutralizing capacity of 26.3% at 1 month and 43.6% at 3 months, despite positive seroconversion rates of 51.5% and 68.9% at the respective time points. Healthy controls had 93.2% and 100% neutralizing capacity at 1 and 3 months, respectively. Patients with leukemia, lymphoma, and multiple myeloma on observation had uniformly blunted responses. Treatment with Bruton tyrosine kinase inhibitors, venetoclax, phosphoinositide 3-kinase inhibitors, anti-CD19/CD20–directed therapies, and anti-CD38/B-cell maturation antigen–directed therapies substantially hindered responses, but single-agent immunomodulatory agents did not.
UR - http://www.scopus.com/inward/record.url?scp=85122439443&partnerID=8YFLogxK
U2 - 10.1158/2643-3230.BCD-21-0139
DO - 10.1158/2643-3230.BCD-21-0139
M3 - Article
C2 - 34778797
AN - SCOPUS:85122439443
SN - 2643-3230
VL - 2
SP - 568
EP - 576
JO - Blood cancer discovery
JF - Blood cancer discovery
IS - 6
ER -